These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. Heineman TC; Schleiss M; Bernstein DI; Spaete RR; Yan L; Duke G; Prichard M; Wang Z; Yan Q; Sharp MA; Klein N; Arvin AM; Kemble G J Infect Dis; 2006 May; 193(10):1350-60. PubMed ID: 16619181 [TBL] [Abstract][Full Text] [Related]
9. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Kharfan-Dabaja MA; Boeckh M; Wilck MB; Langston AA; Chu AH; Wloch MK; Guterwill DF; Smith LR; Rolland AP; Kenney RT Lancet Infect Dis; 2012 Apr; 12(4):290-9. PubMed ID: 22237175 [TBL] [Abstract][Full Text] [Related]
10. Live cytomegalovirus vaccination of renal transplant candidates. A preliminary trial. Glazer JP; Friedman HM; Grossman RA; Starr SE; Barker CF; Perloff LJ; Huang ES; Plotkin SA Ann Intern Med; 1979 Nov; 91(5):676-83. PubMed ID: 227299 [TBL] [Abstract][Full Text] [Related]
11. The status of cytomegalovirus vaccine. Starr SE; Friedman HM; Plotkin SA Rev Infect Dis; 1991; 13 Suppl 11():S964-5. PubMed ID: 1664136 [TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Griffiths PD; Stanton A; McCarrell E; Smith C; Osman M; Harber M; Davenport A; Jones G; Wheeler DC; O'Beirne J; Thorburn D; Patch D; Atkinson CE; Pichon S; Sweny P; Lanzman M; Woodford E; Rothwell E; Old N; Kinyanjui R; Haque T; Atabani S; Luck S; Prideaux S; Milne RS; Emery VC; Burroughs AK Lancet; 2011 Apr; 377(9773):1256-63. PubMed ID: 21481708 [TBL] [Abstract][Full Text] [Related]
13. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. Lowance D; Neumayer HH; Legendre CM; Squifflet JP; Kovarik J; Brennan PJ; Norman D; Mendez R; Keating MR; Coggon GL; Crisp A; Lee IC N Engl J Med; 1999 May; 340(19):1462-70. PubMed ID: 10320384 [TBL] [Abstract][Full Text] [Related]
15. A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor. Vincenti F; Budde K; Merville P; Shihab F; Ram Peddi V; Shah M; Wyburn K; Cassuto-Viguier E; Weidemann A; Lee M; Flegel T; Erdman J; Wang X; Lademacher C Am J Transplant; 2018 Dec; 18(12):2945-2954. PubMed ID: 29745007 [TBL] [Abstract][Full Text] [Related]
16. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. Balfour HH; Chace BA; Stapleton JT; Simmons RL; Fryd DS N Engl J Med; 1989 May; 320(21):1381-7. PubMed ID: 2541335 [TBL] [Abstract][Full Text] [Related]
17. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. Adler SP; Starr SE; Plotkin SA; Hempfling SH; Buis J; Manning ML; Best AM J Infect Dis; 1995 Jan; 171(1):26-32. PubMed ID: 7798679 [TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus vaccines: current status. Starr SE Infect Agents Dis; 1992 Jun; 1(3):146-8. PubMed ID: 1365538 [TBL] [Abstract][Full Text] [Related]